DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Abrocitinib
Abrocitinib
Stanford Chem-H Presentation (PDF)
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Stem Cell/Wnt
Frontiers in Dermatology and Venereology - a Series of Theme Issues in Relation to the 100-Year Anniversary of Actadv
Key Potential Drug Launches in 2021
February 2021 EPS Pipeline Report
JAK/STAT Signaling
Immune-Related Genes: Potential Regulators and Drug Therapeutic Targets in Hypertrophic Cardiomyopathy
Supplementary Materials
Rxoutlook® 4Th Quarter 2020
E-Poster List
Atopic Dermatitis: Effectiveness and Value
TAG Mail – 26 August 2021 COVID-19 RESOURCES & ARTICLES of INTEREST Please Click This Link for the Cumulative Listing of COVID-19 Resources in Past TAG Mails
49Th Annual ESDR Meeting September 18–21, 2019 Bordeaux, France
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
Efficacy and Safety of Abrocitinib in Adults and Adolescents With
Ulipristal Acetate
OCTOBER 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Top View
Another Alzheimer's Failure: Crenezumab Bites the Dust
Sareum Holdings Healthcare 4 May 2021
Pfizer Pipeline
Journal for Immunotherapy of Cancer (JITC) Preprint
Investigations of SKIN INFLAMMATION with a NOVEL DERMATOLOGY TOOLBOX for EARLY PHASE CLINICAL DRUG DEVELOPMENT
Q1 2020 PFE Earnings Press Release
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
Advances in Atopic Dermatitis
(CHMP) Agenda for the Meeting on 21-24 June 2021
JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis: Effectiveness and Value
Coral Lérida Guardado Curso 2019/2020
A View Into Upcoming Specialty & Traditional Drugs
CHMP Agenda of the 25-29 January 2021 Meeting
Pfizer Reports Fourth-Quarter and Full-Year 2020 Results and Releases 5-Year Pipeline Metrics
TAG Mail – 17 Dec 2020
ATC/DDD Classification (Temporary)
JAK/STAT Signaling
EAMS Treatment Protocol
February 2021 Pipeline Report
Stem Cell/Wnt
JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results
Breakthroughs That Change Patients' Lives
( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0405883 A1 BILIC Et Al
Specialty Pipeline Monthly Update June 2021
A Mathematical Model to Identify Optimal Combinations of Drug
Atopic Dermatitis: Beneath the Surface Individualizing Care for Patients with Moderate-To-Severe Disease
Application of Janus Kinase Inhibitors in Atopic Dermatitis: an Updated Systematic Review and Meta-Analysis of Clinical Trials
Selida Poster S07-20
Rxoutlook® 1St Quarter 2021
(CHMP) Agenda for the Meeting on 12-15 October 2020
Table of Contents Manufacturers
Dic.2020-8-5.Pdf
Specialty Pipeline MONTHLY UPDATE
JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis
Janus Kinase
Mediated Inflammatory Diseases with Janus Kinase Inhibitors
Optumrx Drug Pipeline Insights Report
Old Drugs for JAK-STAT Pathway Inhibition in COVID-19 Patients
Generic Pipeline Forecast This Section Provides a Summary of Upcoming First-Time Generic Drugs and Biosimilars That May Be Approved in the Upcoming Two Years